PMID- 29692616
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - IL-21-secreting hUCMSCs combined with miR-200c inhibit tumor growth and 
      metastasis via repression of Wnt/beta-catenin signaling and epithelial-mesenchymal 
      transition in epithelial ovarian cancer.
PG  - 2037-2050
LID - 10.2147/OTT.S147855 [doi]
AB  - BACKGROUND: Epithelial ovarian cancer (EOC) with insidious characteristic 
      manifests no symptoms in its early onset but most patients have advanced and 
      distant cancer metastasis at diagnosis. Innovative early diagnosis and effective 
      treatment of EOC are urgently needed. METHODS: In the study, we developed a novel 
      agent of IL-21-secreting human umbilical cord mesenchymal stem cells (hUCMSCs) 
      combined with miR-200c to evaluate its effects on SKOV3 EOC in vitro and in vivo. 
      RESULTS: hUCMSCs-LV-IL-21 combined with miR-200c significantly inhibited the 
      SKOV3 cell mobility and tumorigenesis compared with hUCMSCs-LV-IL-21, 
      hUCMSCs-LV-vector, and hUCMSCs, respectively. These were reflected in decreasing 
      the tumor sizes and elongating the tumor bearing nude mouse survival, accompanied 
      with increasing the serum cytokine levels of IFN-gamma, IL-21 and TNF-alpha as well as 
      the splenocyte cytotoxicity. In addition, the expression of beta-catenin, cyclin-D1, 
      Gli1, Gli2, and ZEB1 was decreased but the E-cadherin expression was increased in 
      tumor tissues of mice treated with hUCMSCs-LV-IL-21 plus miR-200c. CONCLUSION: We 
      demonstrated that the synergistic effect of fighting SKOV3 EOC is attributable to 
      repression of Wnt/beta-catenin signaling and epithelial-mesenchymal transition in 
      SKOV3 EOC. The findings may provide a new strategy for therapy of EOC.
FAU - Zhang, Yunxia
AU  - Zhang Y
AD  - Department of Pathogenic Biology and Immunology, School of Medicine, Southeast 
      University, Nanjing, People's Republic of China.
AD  - Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, 
      Southeast University, Nanjing, People's Republic of China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, 
      Southeast University, Nanjing, People's Republic of China.
FAU - Wu, Di
AU  - Wu D
AD  - Department of Pathogenic Biology and Immunology, School of Medicine, Southeast 
      University, Nanjing, People's Republic of China.
FAU - Li, Miao
AU  - Li M
AD  - Department of Pathogenic Biology and Immunology, School of Medicine, Southeast 
      University, Nanjing, People's Republic of China.
FAU - Zhao, Fenshu
AU  - Zhao F
AD  - Department of Pathogenic Biology and Immunology, School of Medicine, Southeast 
      University, Nanjing, People's Republic of China.
FAU - Ren, Mulan
AU  - Ren M
AD  - Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, 
      Southeast University, Nanjing, People's Republic of China.
FAU - Cai, Yunlong
AU  - Cai Y
AD  - Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, 
      Southeast University, Nanjing, People's Republic of China.
FAU - Dou, Jun
AU  - Dou J
AD  - Department of Pathogenic Biology and Immunology, School of Medicine, Southeast 
      University, Nanjing, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20180410
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5901132
OTO - NOTNLM
OT  - IL-21
OT  - Wnt/beta-catenin signaling
OT  - epithelial ovarian cancer
OT  - epithelial-mesenchymal transition
OT  - miR-200c
OT  - umbilical cord mesenchymal stem cells
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/04/26 06:00
MHDA- 2018/04/26 06:01
PMCR- 2018/04/10
CRDT- 2018/04/26 06:00
PHST- 2018/04/26 06:00 [entrez]
PHST- 2018/04/26 06:00 [pubmed]
PHST- 2018/04/26 06:01 [medline]
PHST- 2018/04/10 00:00 [pmc-release]
AID - ott-11-2037 [pii]
AID - 10.2147/OTT.S147855 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Apr 10;11:2037-2050. doi: 10.2147/OTT.S147855. 
      eCollection 2018.